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Background: Isoflavone-containing soy products modulate allergic inflammation in mice. In our previously study,
IFN-γ and IL-10 production increased in mice fed with Saccharomyces cerevisiae legume fermented product (SCLFP),
demonstrating that SCLFP had immunomodulatory activity. In this study, we tested the anti-inflammatory effects of
SCLFP in a mouse model of cutaneous atopic dermatitis inflammation induced by epicutaneous sensitization.
Methods: Epicutaneous exposure to protein allergens plus Staphylococcal enterotoxin B induced a T helper
(Th)-2–dominant immune response as well as cutaneous atopic dermatitis-like inflammation in BALB/c mice.
The thickness of the skin epithelium, eosinophil migration, and T helper responses were determined in patched
skin and draining lymph nodes of mice fed with and without SCLFP.
Results: Epicutaneous exposure to protein allergens plus Staphylococcal enterotoxin B induced a T helper
(Th)-2–dominant immune response as well as cutaneous atopic dermatitis-like inflammation in BALB/c mice. SCLFP
feeding attenuated this cutaneous Th2 response, as evidenced by decreased thickening of the epidermis, less eosinophil
infiltration, and lower levels of IL-5, IL-13, and CXCL11 expression compared to controls. Oral administration of SCLFP also
modulated Th1 responses in draining lymph nodes, with lower levels of IFN-γ, IL-4, and IL-17 expression.
Conclusion: Oral intake of SCLFP modulated the induced Th2 inflammatory responses in skin and might have potential
applications for the prevention and treatment of atopic dermatitis.
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Atopic dermatitisBackground
Atopic dermatitis is a common cutaneous inflammatory
disease. The etiology of this condition is complex, involving
abnormal immunological responses to environmental
protein allergens and defective skin barriers [1]. Most
atopic dermatitis patients have elevated total serum
immunoglobulin (Ig) E levels and specific IgE antibodies
to environmental allergens [2]. Acute atopic dermatitis
skin lesions exhibit T-helper (Th)-2–dominant inflam-
mation characterized by infiltration of CD4+ T cells and* Correspondence: lifangwa@ntu.edu.tw; chiajs@ntu.edu.tw
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unless otherwise stated.eosinophils, as well as increased expression of Th2 cyto-
kines including interleukin (IL)-4, IL-5, and IL-13 [3].
Chronic atopic dermatitis lesions demonstrate a Th2
plus Th1 response and tissue remodeling with increased
collagen deposition and dermal thickening [4,5].
In contrast to the highly diversified bacterial population
on normal skin, more than 90% of colonized bacteria in
atopic dermatitis lesions are Staphylococcus aureus [6,7].
Staphylococcal enterotoxin B (SEB), a S. aureus-derived
super-antigen, contributes to the propagation of cutaneous
inflammation and has been employed in epicutaneous
sensitization to establish murine atopic dermatitis models.
Epicutaneous exposure to ovalbumin (OVA)/SEB has been
shown to induce elevated antigen-specific serum IgE levels
[8] and dermal infiltration of eosinophils, mast cells, and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Composition of Saccharomyces cerevisiae legume
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expression profile. Epicutaneous sensitization with OVA
also induces a Th17 and Th9 response [9,10].
Products of soybean fermentation are common food
sources in Asian countries. Isoflavones, including genistein
and daidzein, are a major component of soy fermented
products. These compounds are reported to have anti-
inflammatory and antioxidant effects [11]. Miyake et al.
reported that a high intake of isoflavones may be associated
with a reduced prevalence of allergenic rhinitis in humans
[12]. Smith et al. reported that increased consumption
of genistein was associated with better lung function in
patients with asthma [13]. Kalhan et al. further demon-
strated that soy genisteins inhibit eosinophilic airway
inflammation [14]. In animal models, many reports have
shown that administration of isoflavones has beneficial
effects on asthma [15,16]. Genistein has been shown to
suppress the development of spontaneous atopic-like
dermatitis in NC/Nga mice [17]. Furthermore, topical
isoflavones reduce experimental cutaneous inflammation
induced by UVB irradiation [11].
Soybean products can be metabolized by intestinal
micro-organisms to generate prebiotics. These prebi-
otics can promote the growth of beneficial bacteria and
maintain the integrity of the epithelial barrier of the
gut [18]. The fermented legume product Saccharomyces
cerevisiae legume fermented product (SCLFP), sold as
BN222, is prepared by fermentation of soybean milk
nutrition broth by Lactobacillus paracasei and Saccharo-
myces cerevisiae. This product has been used for human
dietary supplementation world-wide for several years. In
this study, we ask whether this fermented soy-derived-
fermented food can modulate a T helper response to
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1SCLFP composition was analyzed by HPLC/DAD (SGS, Taiwan Ltd); 2data are
presented as % of total isoflavone content.Methods
SCLFP preparation
SCLFP (sold as BN222), a fermentation product of a mix-
ture of soybeans, black beans, and green beans, was
provided by AKC Nutraceuticals Inc., British Columbia,
Canada. The microorganisms used in the fermentation
process were Lactobacillus paracasei and Saccharomyces
cerevisiae. The nutrient broth used in fermentation was
prepared by mixing organic beans (mainly soybeans, black
beans, and green beans) with distilled water, followed by
grinding, and heat sterilizing (at 100°C). The microor-
ganisms were inoculated into the mixed bean nutrient
broth (1.08 x108 CFU/mL) and incubated for 150 h. The
final fermented broth was then heat-sterilized, filtered,
concentrated, and spray dried. The resulting pathogen-
free powders were then packaged into capsules. SCLFP
contains oligosaccharides, including fucose, rhamnose,
glucosamine, galactose, glucose, mannose, and xylose. Thecomposition of SCLFP is 83.37% isoflavones, including
70.1% daidzein, 7.16% genistein, 2.15% genistin and 3.29%
daidzin (Table 1).
Murine model splenocyte stimulation and epicutaneous
sensitization
Female BALB/c mice (6–8 weeks old) were purchased
from the animal center of National Taiwan University,
College of Medicine (Taipei City, Taiwan) and kept in a
specific pathogen-free environment. All animal experi-
ments were approved by the animal care committee of
the Medical College of National Taiwan University.
Splenocytes were isolated from mice fed with SCLFP (3,
6, or 15 mg) 5 days a week for 4 weeks. The splenocytes
were stimulated with 1 μg Concanavalin (Con)A for 3 days,
the culture supernatant were collected for cytokine
determination. Mice were separated into 3 experimental
groups: 1) sham group, which received epicutaneous
sensitization with SEB without OVA and were given water;
2, 3) immunization group and immunization + SCLFP
group, respectively, both of which received epicutaneous
sensitization with OVA+ SEB and were given water
(immunization group) or SCLFP (immunization + SCLFP
group). Briefly, mice were fed with 200 μL of water or
150 mg/mL SCLFP 3 times per week for 8 successive
weeks. For epicutaneous sensitization, 20 μL of 100 mg/
mL OVA (Sigma-Aldrich, St. Louis, MO, USA) and 10 μL
of 400 μg/mL SEB (Sigma-Aldrich, St. Louis, MO, USA)
were placed on the disc of a Finn chamber (Epitest,
Tuusula, Finland). The discs were then applied to an
area of shaved skin on the back of each mouse. For
each course of epicutaneous sensitization, freshly prepared
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neous immunizations were performed at weeks 2, 5, and 8
after the beginning of feeding.
Histological analysis
Skin specimens were obtained from patched areas 8 days
after the third sensitization course and fixed in 10% buff-
ered formalin and embedded in paraffin. Multiple 5-μm
sections were stained with hematoxylin and eosin (H & E)
for evaluation of epidermal thickness and eosinophil count-
ing. The number of eosinophils was counted in 15 high-
power fields at 200 ×magnification (Zeiss, Axio Imager A1)
and presented as cells per high-power field, with mean and
standard error of the mean (SEM) calculated.
RNA preparation
The skin or draining lymph node (DLN) samples were
obtained 8 days after the third sensitization course. Cell
suspensions of pooled (5 mice per group) DLN cells were
prepared from sensitized mice in RPMI 1640 medium
(Thermo Scientific Nunc) supplemented with 10% fetal
bovine serum and antibiotics. Cells were cultured in theFigure 1 Epicutaneous sensitization mouse model. (A) The protocol for e
(B) Mice received either epicutaneous sensitization with PBS plus SEB and wa
with SCLFP (immunization + SCLFP). (C) The appearance of patched skin afterpresence of 50 μg/mL OVA and harvested after 24 h.
After homogenization, the total RNA was extracted
and complementary DNA was synthesized from 2 μg
of DNase-I–treated total RNA. Real-time PCR was
performed using a KAPA SYBR FAST qPCR kit (Kappa
Biosystems, Boston, MA, USA) in a 7500 Real-Time PCR
system (Applied Biosystems, Carlsbad, CA, USA). The rela-
tive cytokine mRNA expression level of each sample was
normalized according to its β-actin expression. The primer
used in this study is listed in Additional file 1: Table S1.
ELISA
Sera were collected 8 days after the third epicutaneous
sensitization and stored at −20°C until further analysis.
OVA-specific antibody levels were determined by ELISA.
Briefly, ELISA plates were coated with 0.5 μg of OVA
per well. After washing and blocking, the plates were
incubated with serial dilutions of serum samples for 18 h
at 4°C. Next, the plates were washed and incubated with
biotin-conjugated antibodies directed against mouse IgG1,
IgG2a, or IgE (Bethyl Laboratories, Montgomery, TX,
USA) for 18 h at 4°C. After washing, samples werepicutaneous sensitization with OVA/SEB and administration of SCLFP.
ter (sham), sensitization with OVA + SEB and water (immunization), or
3 courses of epicutaneous sensitization. Arrows indicate skin lesions.
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ase followed by tetramethylbenzidine substrate (Clinical
Science Product Inc., Mansfield, MA, USA) for detection.
Interferon-γ, IL-10, IL-2, and IL-4 in serum were deter-
mined using the DuoSet ELISA Development System
(R&D, Systems, Inc.).
Statistical analysis
Data are presented as the mean ± standard error of the
mean (SEM) and performed with one-way analysis of
variance (ANOVA) followed by Tukey’s multiple compari-
son test to compare the mean levels of cytokine expression
following a particular treatment. All p-values less than
0.05 were considered statistically significant.
Results
Immunomodulatory effects of SCLFP administration
After 4 weeks of SCLFP administration, the mice were
scarified, the spleens harvested, and single-cell suspensions
were prepared for ConA stimulation. Interferon-γ and IL-10
protein expression increased dose-dependently with SCLFP
administration (Additional file 2: Figure S1A and B). Ex-
pression of IL-2 and IL-4, the Th2-response cytokines
were on the decrease (Additional file 2: Figure S1C and
D). These results demonstrated SCLFP had immune-Figure 2 Histological features of patched skin in BALB/c mice. Mice wer
thickening of the epidermis with mild spongiosis and inflammatory cell infiltra
the 3 groups of mice. Data are presented as the mean ± standard error of the
followed by Tukey’s multiple comparison test to compare each group. All p-vmodulatory potential that drive immune response to Th1
and immunosuppressive response. Therefore, the Th2
epicutaneous sensitization mice model was selected to test
this hypothesis.Oral SCLFP administration with epicutaneous sensitization
attenuated cutaneous inflammation
The effects of oral SCLFP administration on cutaneous
allergic inflammation were explored using the murine epi-
cutaneous sensitization model (Figure 1A,B). As expected,
mice receiving an epicutaneous OVA/SEB patch (immu-
nized group) developed remarkable erythema with scaling
and crust formation on the patched skin (Figure 1C).
In contrast, mice fed SCLFP daily showed significant
attenuation of cutaneous inflammation (Figure 1C). Mice
receiving epicutaneous sensitization with phosphate-
buffered saline (sham group) showed only marginal
erythema (Figure 1C). Histological features were also
examined (Figure 2A). In the immunized group, the
patched skin showed acanthosis, spongiosis, and inflam-
matory cell infiltration of the dermis. The epidermis was
markedly thickened (68.21 ± 10.20 μm) in the immunized
group compared to that of the sham group (42.29 ±
8.180 μm). SCLFP administration significantly reduced thee epicutaneously sensitized and fed as shown in Figure 1. (A) Marked
tion in the dermis. (B) Epidermal thickness was determined in each of
mean (SEM) and performed with one-way analysis of variance (ANOVA)
alues less than 0.05 were considered statistically significant.
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(Figure 2B). These results demonstrated that treatment
with SCLFP attenuated the cutaneous inflammation in-
duced by epicutaneous OVA/SEB sensitization.
SCLFP administration with epicutaneous sensitization
attenuated eosinophil infiltration and Th2 cytokine
expression
The number of eosinophils in the immunized group in-
creased markedly (39.83 ± 6.348 per high-resolution field,
HRF) compared to that of the sham group (6.333 ± 1.411
per HRF; p = 0.0002) (Figure 3A). Notably, the number
of eosinophils in the SCLFP group was much lower
(1.250 ± 0.1306 per HRF) than that of the immunized
group (p < 0.0001).
The Th2 expression levels of IL-5 and IL-13 in induced
cutaneous inflammation of the immunized group mark-
edly increased over that of controls. The expression levels
of IL-5 and IL-13 were significantly lower in the SCLFP
group than in the immunized group (IL-5, p = 0.0132;
IL-13, p = 0.0130) (Figure 3B). The expression level of
CCL11, a Th2 chemokine for eosinophil migration, was
much lower in the SCLFP group than in the immunized
group (Figure 3C). Furthermore, Th2-related antigen-
specific antibody production, including IgG1, and IgE,Figure 3 The Th2-induced cutaneous inflammation was attenuated w
Figures 1 and 2. (A) Eosinophil counts in induced cutaneous inflammation;
(C) in induced cutaneous inflammation. Data are presented as values norm
performed with one-way analysis of variance (ANOVA) followed by Tukey’s
0.05 were considered statistically significant.increased in the immunized group (Additional file 3:
Figure S2). SCLFP administration had no effect on the
production of these antibodies. Collectively, epicutaneous
sensitization with OVA/SEB induced a Th2-predominant
cutaneous inflammation that could be attenuated by
oral co-administration of SCLFP, but did not affect IgE
production.SCLFP administration modulates T helper responses in
draining lymph nodes
Epicutaneous sensitization with a protein antigen induced
predominant Th2, a modest Th17, and a marginal Th1 re-
sponse [8,10,19]. The expression level of IL-4 and IL-10 in
draining lymph nodes (DLN) was highly elevated in the
immunized group compared to that of the sham group
(Figure 4), while interferon (IFN)-γ and IL-17A expression
levels were only modestly elevated. Administration of
SCLFP to immunized mice significantly decreased the
expression of IL-4, and IL-17A in DLN (p= 0.007, p= 0.012,
respectively). The expression of IL-10 and interferon –γ also
showed a tendency to decrease, but the difference did not
reach statistical significance. These results supported that
administration of SCFLP could modulate the Th immune
responses induced by epicutaneous sensitization.ith oral administration of SCLFP. Mice were treated as shown in
H&E staining. (B, C) Expression levels of IL-5 and IL-13 (B) and CCL11
alized to β-actin expression and presented as the mean ± SEM and
multiple comparison test to compare each group. All p-values less than
Yeh et al. BMC Complementary and Alternative Medicine 2014, 14:194 Page 6 of 8
http://www.biomedcentral.com/1472-6882/14/194Discussion
In this study, we demonstrated that SCLFP treatment
attenuated cutaneous inflammation, with decreased eo-
sinophil infiltration and Th2 cytokine expression, is in
agreement with a report by Sakai et al., who observed
that genistein administration decreased skin inflammation
in atopic-like dermatitis [17]. However, the administration
of isoflavones decreased Th2 cytokine expression in DLN
in our study; this result contrasts that of the Sakai study,
which reported no difference in serum IgE levels between
genistein-treated and control mice. The reason for this
discrepancy is not clear at present, but we speculate 2 pos-
sibilities. First, the isoflavones we administered (SCLFP)
differ from the genistein used in the Sakai study. Second,
their study used a specific mouse strain that develops
atopic dermatitis-like cutaneous inflammation spontan-
eously, implying an intrinsic abnormal immune response
that might not be reversed by isoflavones. Notably, our re-
sults are consistent with most reports on this topic, whichFigure 4 Cytokine expression in draining lymph nodes. Mice (n = 5) w
week after the third sensitization course. DLN cells were cultured in the pre
cDNA preparation. Expression levels of (A) IFN-γ, (B) IL-4, (C) IL-10, and (D)
the mean ± SEM and performed one-way analysis of variance (ANOVA) follo
were considered statistically significant.demonstrate that isoflavones suppress the induced Th2
response in asthma and food hypersensitivity models [20].
Epicutaneous sensitization with protein antigen induces
a predominant Th2 response that is crucial for the devel-
opment of atopic dermatitis. The development of methods
or strategies to suppress induction of this Th2 response is
very important clinically. Using the murine protein-patch
model for epicutaneous sensitization, we have observed
that most manipulations, including co-administration
of Toll-like receptor (TLR) agonists, irritants, or haptens
enhanced the Th2 response (unpublished results). Of all
the agents we have tested, only low-energy visible light
and co-administration of dectin-1 agonist suppressed the
Th2 response [21,22]. Saegusa et al. reported that galectin-
3 deficient mice exhibited a markedly lower Th2 response
to epicutaneous sensitization with protein antigen com-
pared with wild type mice [23]. Kypriotou et al. recently
demonstrated that activin A, a member of the TGF-β
superfamily, inhibited antigen-induced cutaneous Th2ere treated as shown in Figure 3. DLN were obtained and pooled one
sence of 50 μg/mL OVA. Cells were harvested after 24 h for RNA and
IL-17A were measured using quantitative PCR. Data are represented
wed by Tukey’s multiple comparison test. All p-values less than 0.05
Yeh et al. BMC Complementary and Alternative Medicine 2014, 14:194 Page 7 of 8
http://www.biomedcentral.com/1472-6882/14/194polarization [24]. Thus, our observation that SCLFP sup-
pressed the Th2 response might have potential clinical
applications for preventing and treating atopic dermatitis.
The mechanisms underlying the modulatory effects of
isoflavones are under investigation. Genistein is structur-
ally similar to estradiol and has been suggested to act as
an E2 agonist or antagonist [20] and is also known to be a
protein tyrosine kinase inhibitor [16]. Masilamani et al.
showed that soybean isoflavones regulate dendritic cell
function by inhibiting their maturation by altering co-
stimulator expression and cytokine secretion [25]. Zhang
et al. demonstrated that soy isoflavones down-regulate the
Th2 response and promote the Th1 response [26]. Kalhan
et al. demonstrated that genistein also inhibits eosinophil
leukotriene C4 synthesis [14].
Soybean products can be metabolized to generate pre-
biotics that might modulate immune responses through
changing the propagation of beneficial bacteria [27]. Our
preliminary experiments showed that oral administration
of SCLFP increased the amounts of Lactobacilli in feces
after epicutaneous sensitization (data not shown). There-
fore, SCLFP also has the potential to modulate beneficial
flora populations in the gut, although the mechanism
and extent of such effects needs further confirmation.Conclusions
In summary, this study provides evidence that oral
administration of SCLFP modulates cutaneous atopic
dermatitis-like inflammation in mice and might have
potential applications for the prevention and treatment of
atopic dermatitis.Additional files
Additional file 1: Table S1. Primer list.
Additional file 2: Figure S1. Immunomodulatory effect of SCLFP
administration in splenocytes. Mice were administered the indicated
dose of SCLFP once daily, 5 days per week. After 4 weeks, the mice
were sacrificed, and single-cell suspensions of spleen were prepared for
Concanavalin A stimulation for 3 days. The cultured supernatant was
collected for IFN-γ (A), IL-10 (B), IL-2 (C), and IL-4 (D) determination. Data are
represented the mean ± SEM and performed one-way analysis of variance
(ANOVA) followed by Tukey’s multiple comparison test. All p-values less than
0.05 were considered statistically significant.
Additional file 3: Figure S2. Serum antigen-specific antibody responses
to administration of SCLFP. Sera were collected 8 days after the third
epicutaneous sensitization, and OVA-specific (A) IgG1, (B) IgG2a and (C)
IgE antibody levels were determined by ELISA. Data are represented
the mean ± SEM and performed one-way analysis of variance (ANOVA)
followed by Tukey’s multiple comparison test. All p-values less than 0.05
were considered statistically significant.Abbreviations
SCLFP: Saccharomyces cerevisiae legume fermented product; Th: T helper;
AD: Atopic dermatitis; SEB: Staphylococcal Enterotoxin B; DLN: draining
lymph node; OVA: Ovalbumin.Competing interests
All authors declare no conflicts of interest and agree to submit this study for
publication.
Authors’ contributions
The contributions of all authors are as follows: CYY and LFW contributed to
experimental design, practice, and manuscript preparation; CJJ and WBW
assisted in data analysis and discussing results; CNH, YCH, and HTL performed
animal experiments; JSC was the supervisor and coordinator. All authors read
and approved the final manuscript.
Acknowledgements
This work was supported by the National Science Council NSC 101-2321-B-
002-074 and NSC 101-2321-B-002-016.We thank Bioscience Editing Solutions
and MedCom Asia for providing medical writing services to improve the
grammar and English usage in the manuscript.
Author details
1Graduate Institute of Immunology, College of Medicine, National Taiwan
University, No. 1, Jen Ai Road 1st Section, Taipei City 10051, Taiwan.
2Graduate Institute of Oral Biology, School of Dentistry, National Taiwan
University, No.1, Changde St., Taipei City 100, Taiwan. 3Graduate Institute of
Microbiology, College of Medicine, National Taiwan University, No. 1, Jen Ai
Road 1st Section, Taipei City 10051, Taiwan. 4Department of Dermatology,
College of Medicine, National Taiwan University, No. 1, Jen Ai Road 1st
Section, Taipei 10051, Taiwan.
Received: 7 October 2013 Accepted: 21 May 2014
Published: 18 June 2014
References
1. Leung DY, Bieber T: Atopic dermatitis. Lancet 2003, 361:151–160.
2. Schafer T, Heinrich J, Wjst M, Adam H, Ring J, Wichmann HE: Association
between severity of atopic eczema and degree of sensitization to
aeroallergens in schoolchildren. J Allergy Clin Immunol 1999, 104:1280–1284.
3. Brandt EB, Sivaprasad U: Th2 Cytokines and Atopic Dermatitis. J Clin Cell
Immunol 2011, 2:110.
4. Leung DY, Boguniewicz M, Howell MD, Nomura I, Hamid QA: New insights
into atopic dermatitis. J Clin Invest 2004, 113:651–657.
5. Oh MH, Oh SY, Yu J, Myers AC, Leonard WJ, Liu YJ, Zhu Z, Zheng T: IL-13
induces skin fibrosis in atopic dermatitis by thymic stromal
lymphopoietin. J Immunol 2011, 186:7232–7242.
6. Aly R, Maibach HI, Shinefield HR: Microbial flora of atopic dermatitis. Arch
Dermatol 1977, 113:780–782.
7. Bibel DJ, Greenberg JH, Cook JL: Staphylococcus aureus and the microbial
ecology of atopic dermatitis. Can J Microbiol 1977, 23:1062–1068.
8. Savinko T, Lauerma A, Lehtimaki S, Gombert M, Majuri ML, Fyhrquist-Vanni N,
Dieu-Nosjean MC, Kemeny L, Wolff H, Homey B, Alenius H: Topical superantigen
exposure induces epidermal accumulation of CD8+ T cells, a mixed Th1/Th2-
type dermatitis and vigorous production of IgE antibodies in the murine
model of atopic dermatitis. J Immunol 2005, 175:8320–8326.
9. Lin JY, Chen JS, Hsu CJ, Miaw SC, Liu CY, Lee SJ, Chen PC, Wang LF:
Epicutaneous sensitization with protein antigen induces Th9 cells.
J Invest Dermatol 2012, 132:739–741.
10. Wang LF, Chiu HC, Hsu CJ, Liu CY, Hsueh YH, Miaw SC: Epicutaneous
sensitization with a protein antigen induces Th17 cells. J Dermatol Sci
2009, 54:192–197.
11. Bandara M, Arun SJ, Allanson M, Widyarini S, Chai Z, Reeve VE: Topical
isoflavonoids reduce experimental cutaneous inflammation in mice.
Immunol Cell Biol 2010, 88:727–733.
12. Miyake Y, Sasaki S, Ohya Y, Miyamoto S, Matsunaga I, Yoshida T, Hirota Y,
Oda H: Soy, isoflavones, and prevalence of allergic rhinitis in Japanese
women: the Osaka Maternal and Child Health Study. J Allergy Clin
Immunol 2005, 115:1176–1183.
13. Smith LJ, Holbrook JT, Wise R, Blumenthal M, Dozor AJ, Mastronarde J,
Williams L: Dietary intake of soy genistein is associated with lung
function in patients with asthma. J Asthma 2004, 41:833–843.
14. Kalhan R, Smith LJ, Nlend MC, Nair A, Hixon JL, Sporn PH: A mechanism of
benefit of soy genistein in asthma: inhibition of eosinophil p38-
dependent leukotriene synthesis. Clin Exp Allergy 2008, 38:103–112.
Yeh et al. BMC Complementary and Alternative Medicine 2014, 14:194 Page 8 of 8
http://www.biomedcentral.com/1472-6882/14/19415. Regal JF, Fraser DG, Weeks CE, Greenberg NA: Dietary phytoestrogens have
anti-inflammatory activity in a guinea pig model of asthma. Proc Soc Exp Biol
Med 2000, 223:372–378.
16. Duan W, Kuo IC, Selvarajan S, Chua KY, Bay BH, Wong WS:
Antiinflammatory effects of genistein, a tyrosine kinase inhibitor, on a
guinea pig model of asthma. Am J Respir Crit Care Med 2003, 167:185–192.
17. Sakai T, Kogiso M, Mitsuya K, Komatsu T, Yamamoto S: Genistein
suppresses development of spontaneous atopic-like dermatitis in NC/
Nga mice. J Nutr Sci Vitaminol (Tokyo) 2006, 52:293–296.
18. Rekha CR, Vijayalakshmi G: Bioconversion of isoflavone glycosides to
aglycones, mineral bioavailability and vitamin B complex in fermented
soymilk by probiotic bacteria and yeast. J Appl Microbiol 2010,
109:1198–1208.
19. Wang LF, Lin JY, Hsieh KH, Lin RH: Epicutaneous exposure of protein antigen
induces a predominant Th2-like response with high IgE production in mice.
J Immunol 1996, 156:4077–4082.
20. Sakai T, Kogiso M: Soy isoflavones and immunity. J Med Invest 2008,
55:167–173.
21. Chen JS, Chiu HC, Hsu CJ, Liu CY, Hsieh PC, Miaw S, Yu HS, Wan LF: Low-energy
visible light irradiation modulates immune responses induced by
epicutaneous sensitization with protein antigen. J Invest Dermatol 2009,
129:2258–2264.
22. Lin JY, Chen JS, Chen PC, Chung MH, Liu CY, Miaw SC, Wang LF:
Concurrent exposure to a dectin-1 agonist suppresses the Th2 response
to epicutaneously introduced antigen in mice. J Biomed Sci 2013, 20:1.
23. Saegusa J, Hsu DK, Chen HY, Yu L, Fermin A, Fung MA, Liu FT: Galectin-3 is
critical for the development of the allergic inflammatory response in a
mouse model of atopic dermatitis. Am J Pathol 2009, 174:922–931.
24. Kypriotou M, Rivero D, Haller S, Mariotto A, Huber M, cha-Orbea H, Werner S,
Hohl D: Activin a inhibits antigen-induced allergy in murine epicutaneous
sensitization. Front Immunol 2013, 4:246.
25. Zhang T, Pan W, Takebe M, Schofield B, Sampson H, Li XM: Therapeutic
effects of a fermented soy product on peanut hypersensitivity is
associated with modulation of T-helper type 1 and T-helper type 2
responses. Clin Exp Allergy 2008, 38:1808–1818.
26. Masilamani M, Wei J, Bhatt S, Paul M, Yakir S, Sampson HA: Soybean
isoflavones regulate dendritic cell function and suppress allergic
sensitization to peanut. J Allergy Clin Immunol 2011, 128:1242–1250.
27. Chen KI, Erh MH, Su NW, Liu WH, Chou CC, Cheng KC: Soyfoods and
soybean products: from traditional use to modern applications.
Appl Microbiol Biotechnol 2012, 96:9–22.
doi:10.1186/1472-6882-14-194
Cite this article as: Yeh et al.: A legume product fermented by
Saccharomyces cerevisiae modulates cutaneous atopic dermatitis-like
inflammation in mice. BMC Complementary and Alternative Medicine
2014 14:194.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
